

INVITED LECTURE PRESENTATION

Open Access

Early-onset inflammatory bowel disease caused by mutant IL10 receptor

E O Glocker¹⁺, D Kotlarz²⁺, K Boztug²⁺, E M Gertz³, A A Schäffer³, F Noyan², M Perro¹, J Diestelhorst², A Allroth², D Murugan², N Hätscher², D Pfeifer⁴, K W Sykora², M Sauer², H Kreipe⁵, M Lacher⁶, R Nustede⁷, C Woellner¹, U Baumann⁸, U Salzer⁹, S Koletzko⁶, N Shah¹⁰, A W Segal¹¹, A Sauerbrey¹², S Buderus¹³, S B Snapper¹⁴, B Grimbacher^{1*+}, C Klein^{2*+}

From 5th European Workshop on Immune-Mediated Inflammatory Diseases Sitges-Barcelona, Spain. 1-3 December 2010

Background

The molecular etiology of inflammatory bowel diseases (IBD) is largely unknown.

Methods

We performed genetic linkage analysis and candidate gene sequencing in two unrelated consanguineous families with children affected by early-onset IBD. We screened six additional patients for mutations in two candidate genes and carried out functional assays in patients' peripheral blood mononuclear cells. We treated one patient with an allogeneic hematopoietic stem cell transplant (HSCT).

Results

We identified three distinct homozygous mutations in the genes <code>IL10RA</code> and <code>IL10RB</code>, encoding the <code>IL10R1</code> and <code>IL10R2</code> proteins, respectively (which form a heteromer to make up the interleukin-10 receptor) in four of nine patients with early-onset colitis. The mutations abrogate <code>IL10-induced</code> signaling, as demonstrated by deficient STAT3 phosphorylation upon <code>IL10</code> stimulation. Consistent with this observation is the increased secretion of <code>TNFa</code> and other proinflammatory cytokines from peripheral blood mononuclear cells from <code>IL10R-deficient</code> patients, suggesting that <code>IL10-dependent</code> "negative feedback" regulation is disrupted in these cells. One patient was successfully treated by an allogeneic HSCT.

Mutations in genes encoding the IL10R subunit proteins cause human enterocolitis, involving hyperinflammatory immune responses in the intestine. Allogeneic HSCT may offer a cure for IL10 receptor deficiency.

Author detail:

¹Dept. of Immunology, Royal Free Hospital and University College London, London, UK. ²Dept. of Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany. ³National Center for Biotechnology Information, NIH, DHHS, Bethesda, MD, USA. ⁴Dept. of Hematology/Oncology, Core Facility II Genomics, Freiburg University Medical Center, Freiburg, Germany. ⁵Dept. of Pathology, Hannover Medical School, Hannover, Germany. ⁶Dr. von Hauner'sches Kinderspital, Ludwig-Maximilian University, Munich, Germany. ⁷Dept. of Pediatric Surgery, Hannover Medical School, Hannover, Germany. ⁸Dept. of Pediatric Pulmonology, Hannover Medical School, Hannover, Germany. ⁹Dept. of Rheumatology and Clinical Immunology, University Hospital Freiburg, Freiburg, Germany. ¹⁰Dept. of Paediatric Gastroenterology, Great Ormond Street Hospital, University College London, London, UK. ¹¹Dept. of Medicine, University College London, London, UK. ¹²Dept. of Pediatrics, HELIOS Hospital Erfurt, Erfurt, Germany. ¹³Dept. of Pediatrics, St.-Marien-Hospital Bonn, Bonn, Germany. ¹⁴Massachusetts General Hospital, Harvard Medical School, Boston MA, USA.

Published: 25 November 2010

doi:10.1186/1479-5876-8-S1-I12

Cite this article as: Glocker *et al.*: **Early-onset inflammatory bowel disease caused by mutant IL10 receptor.** *Journal of Translational Medicine* 2010 **8**(Suppl 1):112.

Full list of author information is available at the end of the article



Conclusions

[†] Contributed equally

¹Dept. of Immunology, Royal Free Hospital and University College London, London, UK

²Dept. of Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany